Future of European Pharmaceutical Distribution, The

The impact of DTP on manufacturers and wholesalers

Following developments in the UK, it was expected that direct-to-pharmacy distribution models would be introduced in other major European markets. But, in 2010 there was no sign that DTP was being explored in France and Germany.

Pharmaceutical Distribution in the US

Current and Future Perspectives

Comprehensive overview of the business of pharmaceutical distribution in the US. Full analysis of the challenges facing the sector, plus 17 case studies.

Mergers and Acquisitions in the Pharmaceuticals Sector, 2009

Critical success factors for competing in a consolidating market

Explores the merits of mega-deal in contrast to a more measured portfolio growth strategy and highlights the key opportunities and challenges presented by both business models

Manufacturing in the Global Pharmaceuticals Industry

Key drivers, company strategies and regulations (3rd Edition)

The new edition of this best-selling report offers insight into the manufacturing process, strategy, issues and drivers from an expert author.

Virtual Pharma

The radical route to success

An authoritative explanation of the virtual pharma business model and its implications for the market.

Evaluate Pharma-Yearbook

Company Performance Tables

Essential reading for everybody in the pharmaceutical market from senior executives and corporate strategists

The Rise of Mid-Sized Pharma

What makes mid-sized companies successful – and what big Pharma can learn from them?

Since the year 2000 mid-sized pharmaceutical companies have out performed their larger rivals – they have grown more rapidly, produced better profits and have performed far better on the world’s stock markets.

Pharmaceutical Distribution in Europe

The Emergence of Direct-to-Pharmacy Supply

Comprehensively reviews the business of medicines distribution in Europe

Pharmaceutical Parallel Trade in the United Kingdom, 2000-2006

Market Insights and Trends in a Primary Import Destination

Directory of Contract Pharmaceutical Manufacturers (CMP)

Europe 2006

Directory to over 150 pharmaceutical contract manufacturers in Europe...

Parallel Trade in Pharmaceuticals

Past and future scenarios

The parallel trade of pharmaceutical products is one of the most controversial issues in the pharmaceutical industry. In this 'grey' market, ethical companies loose control of their distribution chains and parallel traders profit from price differentials...

New Trends in European Pharmacy

This report analyses the development of pharmacy systems in Europe; in the 15 member states of the European Union (EU), the EU-applicant countries of central and eastern Europe and some others.

A Healthy Business

A guide to the global pharmaceutical industry

A jargon-free guide to the industry and its various components. Follows development of a drug from the early R&D stages to clinical trials, launch, post marketing and product life-cycle. Examines how companies are built, what has been successful, future growth areas and where the industry is headed.

Pharmaceutical Parallel Trade

Between 10 - 15% of all medicines currently being sold to the National Health Service in the UK, are parallel imports representing a turnover of ?600m a year. The lack of price harmonisation for pharmaceutical products within the EU is the main reason why parallel importation is such a profitable concern.

Global Supply Chain

Global Supply Chain

Global Pharmaceutical Pricing

Strategic issues and practical guidelines

Analyses pharmaceutical pricing strategies through extensive use of case studies. Contains detail on tactics used by pharmaceutical companies to maintain market share, detailed descriptions for issues and terms connected with pricing, which can be used as an encyclopaedia of terminology.

Mergers & Acquisitions in Pharmaceuticals

When and how

A step-by-step reference tool to all aspects of M&A Illustrating the changes from the early days of high margins and large-scale price premiums for innovative high tech acquisitions through to the increasing speed to acquire novel new drugs in the 21st century in a bid to reduce R&D and production costs.